Section 1: IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

1.1 PRODUCT IDENTIFIER

Product Name: xGnP® Graphene Nanoplatelets

Product Code: Not available.

1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE OR MIXTURE AND USES ADVISED AGAINST

Use: Additive.

1.3 DETAILS OF THE SUPPLIER OF THE SAFETY DATA SHEET

Address: XG Sciences, Inc.

815 Terminal Road Lansing, MI

48906

Telephone Number: +00 1 517 703 1110

e-mail address for a competent person responsible for the safety

data sheet: m.knox@xgsciences.com

1.4 EMERGENCY TELEPHONE NUMBER

Emergency Telephone Number: ChemTrec International: (202) 483-7616

Section 2: HAZARDS IDENTIFICATION

2.1 CLASSIFICATION OF THE SUBSTANCE OR MIXTURE

Classification in accordance with the Classification Labeling and Packaging Regulation (EC) No 1272/2008

Hazard class Hazard Statement

Aquatic environment - Chronic 3 (Aquatic H412 Harmful to aquatic life with long lasting Chronic 3) effects.

Classification in accordance with the Dangerous Preparations Directive 1999/45/EC

This preparation is classified as not dangerous according to Directive 1999/45/EC.

2.2 LABEL ELEMENTS

Labeling in accordance with the Classification Labeling and Packaging Regulation (EC) No 1272/2008

Signal Word: Not applicable.

Hazard Statement: H412 Harmful to aquatic life with long lasting effects.

Precaution: P102 Keep out of reach of children.

Prevention: P262 Do not get in eyes, on skin, or on clothing.

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

P273 Avoid release to the environment.

Response: Not applicable.

Storage: Not applicable.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN Print date: 2011-09-28 Specification Not available. Page 1 of 9 Revision date: 2010-09-28



Disposal: P501 Dispose of contents and container in accordance with all

local, regional, national and international regulations.

Additional Hazards: Not applicable.

Labeling in accordance with the Dangerous Substances Directive 67/548/EEC

Physical/Chemical Hazards: Not applicable.

Human Health Hazards: Not applicable.

Environmental Hazards: Not applicable.

Other Hazards: See section 11 for more detailed information on health effects and

symptoms.

2.3 OTHER HAZARDS

PBT & vPvB: See section 12.5 for more detailed information on PBT and vPvB.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 MIXTURES

Classification according to Regulation (EC) No 1272/2008 (CLP)

Ingredient	CAS No	EC No	REACH No	Wt. %	Class
Graphite	7782-42-5	231-955-3	Not available.	95 - 100	Not classified as hazardous.
Sulfur	7704-34-9	231-722-6	Not available.	1 - 5	Skin Irrit. 2 H315

Classification according to 67/548/EEC

Ingredient	CAS No	EC No	REACH No	Wt. %	Class
Graphite	7782-42-5	231-955-3	Not available.	95 - 100	Not classified as hazardous.
Sulfur	7704-34-9	231-722-6	Not available.	1 - 5	Xi; R38

Full text of R-, H- and EUH- phrases: see section 16.

Section 4: FIRST AID MEASURES

4.1 DESCRIPTION OF THE FIRST AID MEASURE

Eye: In case of contact, immediately flush eyes with plenty of water. Remove

contact lenses, if worn. If irritation persists, get medical attention.

Skin: In case of contact, immediately flush skin with plenty of soap and

water. Remove contaminated clothing and shoes. Wash clothing before reuse. Call a physician if irritation develops and persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial

respiration. If breathing is difficult, give oxygen. If symptoms persist,

obtain medical attention.

Ingestion: If swallowed, rinse mouth with water, Seek medical attention or call

poison control.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN Print date: 2011-09-28 Specification Not available. Page 2 of 9 Revision date: 2010-09-28



4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE & DELAYED

Eye: May cause eye irritation. Symptoms may include discomfort or pain,

excess blinking and tear production, with possible redness and swelling.

Skin: May cause skin irritation. Symptoms may include redness, edema,

drying, defatting and cracking of the skin.

Inhalation: May cause respiratory tract irritation.

Ingestion: Not applicable under normal conditions of use.

4.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENTS NEEDED

Note to Physicians: Symptoms may not appear immediately.

Specific Treatments: In case of accident or if you feel unwell, seek medical advice

immediately (show the label or MSDS where possible).

Section 5: FIRE FIGHTING MEASURES

5.1 EXTINGUISHING MEDIA

Suitable Extinguishing Media: Treat for surrounding material.

Unsuitable Extinguishing Media: Not available.

5.2 SPECIAL HAZARDS ARISING FROM THE SUBSTANCE OR MIXTURE

Products of Combustion: May include, and are not limited to: oxides of carbon.

5.3 ADVICE FOR FIRE FIGHTERS

Protection of Firefighters: Keep upwind of fire. Wear full fire fighting turn-out gear (full Bunker

gear) and respiratory protection (SCBA).

Section 6: ACCIDENTAL RELEASE MEASURES

6.1 PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES

Use personal protection recommended in Section 8. Isolate the hazard area and deny entry to unnecessary and unprotected personnel.

6.2 ENVIRONMENTAL PRECAUTIONS

Keep out of drains, sewers, ditches, and waterways. Minimize use of water to prevent environmental contamination.

6.3 METHODS FOR CONTAINMENT AND CLEANING - UP

Methods for Containment: Contain and/or absorb spill with inert material (e.g. sand,

vermiculite), then place in a suitable container. Do not flush to sewer or allow to enter waterways. Use appropriate Personal Protective

Equipment (PPE).

Methods for Cleaning-Up: Vacuum or sweep material and place in a disposal container. Avoid

generating dust. Spills of this material are a slipping hazard.

6.4 REFERENCES TO OTHER SECTIONS

See section 8 for further information on protective clothing and equipment and section 13 for advice on waste disposal.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN Print date: 2011-09-28 Specification Not available. Page 3 of 9 Revision date: 2010-09-28



Section 7: HANDLING & STORAGE

7.1 PRECAUTIONS FOR SAFE HANDLING

Handling: Avoid contact with skin and eyes. Keep away from sources of

ignition. Avoid generating dust as the product may form explosive dust/air mixtures. Good housekeeping is important to prevent accumulation of dust. Graphite is electronically conductive; care should be taken to avoid accumulation of dust / powder where it may cause electrical shorting. Use only in well-ventilated areas. When

using do not eat or drink. (See section 8)

General Hygiene Advice: Wash hands before eating, drinking, or smoking. Launder

contaminated clothing before re-use.

7.2 CONDITIONS FOR SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES

Storage: Keep out of the reach of children. Keep container tightly closed and

dry. Do not store at temperatures above 49 °C / 120 °F. (See section

10)

7.3 SPECIFIC END USES(S)

End uses: Not available.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 CONTROL PARAMETERS

Ingredient	UK - Occupational Exposure Limits (TWA)		
	30 mg/m ³ STEL (calculated, inhalable dust);		
	12 mg/m³ STEL (calculated, respirable dust)		
Graphite	10 mg/m³ TWA (inhalable dust); 4 mg/m³ TWA (respirable dust)		
Sulfur	Not available.		

8.2 EXPOSURE CONTROLS

Engineering Controls: Use ventilation adequate to keep exposures (airborne levels of dust,

fume, vapor, etc.) below recommended exposure limits.

Personal Protective Equipment:

Eye/Face Protection: Wear eye/face protection.

Skin Protection:

Hand Protection: Wear suitable gloves.

Body Protection: Wear suitable protective clothing.

Respiratory Protection: Wear appropriate NIOSH approved dust mask or filtering facepiece if

dust is generated.

General Health & Safety

Measures:

Do not eat, smoke or drink where material is handled, processed or stored. Wash hands carefully before eating or smoking. Ensure that eyewash stations and safety showers are close to the workstation

location.

Environmental Exposure Controls:

Maintain levels below Community environmental protection

thresholds.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available.

Version 1.0 / EN

Print date: 2011-09-28

Specification Not available.

Page 4 of 9

Revision date: 2010-09-28



Section 9: PHYSICAL & CHEMICAL PROPERTIES

9.1 INFORMATION ON BASIC PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Powder.

Color:Grey or black.Odour:Odourless.Odour Threshold:Not available.

Physical State: Solid.

pH: Not available. **Melting Point:** Not available. **Boiling Point:** Not available. Flash Point: Not available. **Evaporation Rate:** Not available. Flammability: Not available. **Lower Flammability/Explosive Limit:** Not available. **Upper Flammability/Explosive Limit:** Not available. Vapor Pressure: Not available. Vapor Density: Not available. **Relative Density:** Not available. Solubility: Negligible. Partition coefficient: n-octanol/water: Not available. **Auto-ignition Temperature:** Not available. **Decomposition Temperature:** Not available. Not available. Viscosity: **Explosive Properties:** Not available.

9.2 OTHER INFORMATION

Oxidizing Properties:

Not available.

Section 10: STABILITY & REACTIVITY

Not available.

10.1 REACTIVITY

No dangerous reaction known under conditions of normal use.

10.2 CHEMICAL STABILITY

Stable under normal storage conditions.

10.3 POSSIBILITY OF HAZARDOUS REACTIONS

No dangerous reaction known under conditions of normal use.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN Print date: 2011-09-28 Specification Not available. Page 5 of 9 Revision date: 2010-09-28



10.4 CONDITIONS TO AVOID

Heat. Incompatible materials.

10.5 INCOMPATIBLE MATERIALS

Strong oxidizers. Chlorine trifluoride. Fluorine.

10.6 HAZARDOUS DECOMPOSITION PRODUCTS

May include, and are not limited to: oxides of carbon.

Section 11: TOXICOLOGY INFORMATION

11.1 INFORMATION ON TOXICOLOGICAL EFFECTS

Skin:

Likely Routes of Exposure: Skin contact, eye contact, and inhalation.

Acute Health Effects:

Eye: May cause eye irritation. Symptoms may include discomfort or pain,

excess blinking and tear production, with possible redness and swelling.

May cause skin irritation. Symptoms may include redness, edema, drying,

defatting and cracking of the skin.

Ingestion: Not applicable under normal conditions of use.

Inhalation: May cause respiratory tract irritation.

Acute Toxicity:

Ingredient	LC50	LD50
Graphite	Not available.	Not available.
•		Oral LD50 Rat >3000 mg/kg;
Sulfur	Inhalation LC50 Rat >9.23 mg/L 4 h	Dermal LD50 Rabbit >2000 mg/kg

^{*99} percent of the mixture consists of ingredient(s) of unknown toxicity.

Skin Corrosion/Irritation: Dust may cause skin irritation. **Serious Eye Damage/Irritation:** Dust may cause eye irritation.

Respiratory or Skin Sensitization: Although this product has not been tested, it is not expected to

have sensitizing potential, based on the absence of effects with

the constituents.

STOT-Single Exposure: Based on available data, the classification criteria are not met.

Chronic Health Effects: No known significant effects or critical hazards.

Carcinogenicity: This product is not classified as a carcinogen. **Germ Cell Mutagenicity:** This product is not classified as a mutagen.

Reproductive Toxicity:

Developmental: This product does not contain known reproductive or

developmental toxins.

Fertility: No known significant effects or critical hazards.

STOT-Repeated Exposure: None identified.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN Print date: 2011-09-28 Specification Not available. Page 6 of 9 Revision date: 2010-09-28



Aspiration Hazard: Not expected to occur.

Other Information: Not available.

Section 12: ECOLOGICAL INFORMATION

12.1 TOXICITY

Acute/Chronic Toxicity: No ecological data on the product itself is available.

Ingredient Aquatic Toxicity
Graphite Not available.

Freshwater fish: 96 Hr LC50 Brachydanio rerio: 866 mg/L [static]; 96 Hr LC50 Lepomis macrochirus: <14 mg/L [static]; 96 Hr LC50

Sulfur Oncorhynchus mykiss: >180 mg/L [static]

Contains 99 % of components with unknown hazards to the aquatic environment.

12.2 PERSISTENCE & DEGRADABILITY

Not available.

12.3 BIOACCUMULATIVE POTENTIAL

Bioaccumulation: Not available.

12.4 MOBILITY IN SOIL

Not available.

12.5 RESULTS OF PBT AND vPvB ASSESSMENT

PBT results: A PBT assessment has not yet been carried out under REACH

for the constituents. However, there are no indications that this product contains substances likely to be classified as PBT.

vPvB results: A vPvB assessment has not yet been carried out under REACH

for the constituents. However, there are no indications that this product contains substances likely to be classified as vPvB.

12.6 OTHER ADVERSE EFFECTS

No other known adverse effects.

Section 13: DISPOSAL CONSIDERATIONS

13.1 WASTE TREATMENT METHODS

Disposal Method: This material must be disposed of in accordance with all

local, state, provincial, and federal regulations.

Other disposal recommendations: Not available.

Section 14: TRANSPORTATION INFORMATION

14.1 UN NUMBER

Not regulated.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available.

Version 1.0 / EN

Print date: 2011-09-28

Specification Not available.

Page 7 of 9

Revision date: 2010-09-28



14.2 UN PROPER SHIPPING NAME

Not applicable.

14.3 TRANSPORT HAZARD CLASS(ES)

Not applicable.

14.4 PACKING GROUP

Not applicable.

14.5 ENVIRONMENTAL HAZARDS

Not available.

14.6 SPECIAL PRECAUTIONS FOR USER

Not available.

14.7 TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE

Not available.

Section 15: REGULATORY INFORMATION

15.1 SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS/ LEGISLATIONS SPECIFIC FOR THE SUBSTANCE OR MIXTURE

Authorizations and/or restrictions on use:

All components are listed as existing substances in Europe.

15.2 CHEMICAL SAFETY ASSESTMENT

A Chemical Safety Assessment has not been carried out for this product.

Section 16: OTHER INFORMATION

Date of Preparation: September 28, 2011

Version:

Revision Date: September 28, 2011

Revised Changes: None.

Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]:

Classification	Classification Procedure	
Aquatic environment - Chronic 3 (Aquatic		
Chronic 3)	Calculation method.	

Relevant R-, H- and EUH- Phrases:

- H412 Harmful to aquatic life with long lasting effects.
- P102 Keep out of reach of children.
- P262 Do not get in eyes, on skin, or on clothing.
- P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
- P273 Avoid release to the environment.

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available.

Version 1.0 / EN

Print date: 2011-09-28

Specification Not available.

Page 8 of 9

Revision date: 2010-09-28



P501 Dispose of contents and container in accordance with all local, regional, national and international regulations.

Legend:

PBT - Persistent, Bioaccumulative and Toxic vPvB - very Persistent and very Bioaccumulative CAS No - Chemical Abstracts Service Number EC No - European Commission Number REACH No - Registration, Evaluation, Authorisation and restriction of Chemicals Number STOT Specific target organ toxicity logK_{o/w} - Partition coefficient n-octanol/water BCF - Bioconcentration Factor

Disclaimer: We believe the statements, technical information and recommendations contained herein are reliable, but they are given without warranty or guarantee of any kind. The information contained in this document applies to this specific material as supplied. It may not be valid for this material if it is used in combination with any other materials. It is the user's responsibility to satisfy oneself as to the suitability and completeness of this information for the user's own particular use.

Prepared by: Nexreg Compliance Inc.

Phone: (519) 488-5126

www.nexreg.com

Prepared for: XG Sciences, Inc

End of Safety Data Sheet

Trade Name: xGnP® Graphene Nanoplatelets

Product No: Not available. Version 1.0 / EN
Specification Not available. Page 9 of 9



Print date: 2011-09-28

Revision date: 2010-09-28